Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence.

Sharma P, Kumar R, Singh H, Jeph S, Sharma DN, Bal C, Malhotra A.

Clin Nucl Med. 2012 Jul;37(7):649-55. doi: 10.1097/RLU.0b013e31824d24fa.

PMID:
22691505
2.

Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.

Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.

Nucl Med Commun. 2012 Jun;33(6):591-6. doi: 10.1097/MNM.0b013e3283516716.

PMID:
22334135
3.

The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: a comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker.

Ozcan Kara P, Kara T, Kaya B, Kara Gedik G, Sari O.

Rev Esp Med Nucl Imagen Mol. 2012 Sep;31(5):257-60. doi: 10.1016/j.remn.2011.06.001. Epub 2011 Aug 6.

4.

Diagnostic accuracy of ¹⁸F-FDG PET/CT for detection of suspected recurrence in patients with oesophageal carcinoma.

Sharma P, Jain S, Karunanithi S, Pal S, Julka PK, Thulkar S, Malhotra A, Bal C, Kumar R.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1084-92. doi: 10.1007/s00259-013-2664-8. Epub 2014 Jan 17.

PMID:
24435775
5.

18F-FDG PET-CT for detecting recurrent gastric adenocarcinoma: results from a Non-Oriental Asian population.

Sharma P, Singh H, Suman SK, Sharma A, Reddy RM, Thulkar S, Bal C, Malhotra A, Kumar R.

Nucl Med Commun. 2012 Sep;33(9):960-6. doi: 10.1097/MNM.0b013e328355b694.

PMID:
22692579
6.

Role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma.

Kumar R, Sharma P, Kumari A, Halanaik D, Malhotra A.

Clin Nucl Med. 2012 May;37(5):431-5. doi: 10.1097/RLU.0b013e31824d24c4.

PMID:
22475890
7.

Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging.

Sharma P, Kumar R, Singh H, Jeph S, Sharma JB, Jain SK, Sharma DN, Bal C, Malhotra A.

Nucl Med Commun. 2012 Feb;33(2):185-90. doi: 10.1097/MNM.0b013e32834e41a6.

PMID:
22107993
8.

Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.

Chang HT, Hu C, Chiu YL, Peng NJ, Liu RS.

PLoS One. 2014 Dec 17;9(12):e115127. doi: 10.1371/journal.pone.0115127. eCollection 2014.

9.

The role of ¹⁸F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making?

Bilici A, Ustaalioglu BB, Seker M, Kefeli U, Canpolat N, Tekinsoy B, Ozugur S, Gumus M.

Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):64-73. doi: 10.1007/s00259-010-1611-1. Epub 2010 Sep 14.

PMID:
20838995
10.

Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.

Dennis K, Hay JH, Wilson DC.

Clin Oncol (R Coll Radiol). 2012 Dec;24(10):e168-72. doi: 10.1016/j.clon.2012.08.002. Epub 2012 Sep 1.

PMID:
22944464
11.

The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.

Sanli Y, Kuyumcu S, Ozkan ZG, Kilic L, Balik E, Turkmen C, Has D, Isik G, Asoglu O, Kapran Y, Adalet I.

Ann Nucl Med. 2012 Aug;26(7):551-8. doi: 10.1007/s12149-012-0609-0. Epub 2012 May 30.

PMID:
22644560
12.

Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.

Ozkan E, Soydal C, Kucuk ON, Ibis E, Erbay G.

Nucl Med Commun. 2011 Dec;32(12):1162-8. doi: 10.1097/MNM.0b013e32834bbe09.

PMID:
21946617
13.

Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.

Artiko V, Odalovic S, Sobic-Saranovic D, Petrovic M, Stojiljkovic M, Petrovic N, Kozarevic N, Grozdic-Milojevic I, Obradovic V.

Hell J Nucl Med. 2015 Jan-Apr;18(1):35-41.

14.

Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities.

Antunovic L, Cimitan M, Borsatti E, Baresic T, Sorio R, Giorda G, Steffan A, Balestreri L, Tatta R, Pepe G, Rubello D, Cecchin D, Canzonieri V.

Clin Nucl Med. 2012 Aug;37(8):e184-8. doi: 10.1097/RLU.0b013e31825b2583.

PMID:
22785525
16.

Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.

Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.

Interact Cardiovasc Thorac Surg. 2010 Jun;10(6):1009-14. doi: 10.1510/icvts.2009.227538. Epub 2010 Mar 2.

PMID:
20197344
17.

Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?

Bilici A, Ustaalioglu BB, Seker M, Canpolat N, Tekinsoy B, Salepci T, Gumus M.

Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1259-69. doi: 10.1007/s00259-010-1416-2. Epub 2010 Mar 23.

PMID:
20309683
18.

Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment.

Robin P, Abgral R, Valette G, Le Roux PY, Keromnes N, Rousset J, Potard G, Palard X, Marianowski R, Salaun PY.

Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):72-8. doi: 10.1007/s00259-014-2889-1. Epub 2014 Aug 29.

PMID:
25169701
19.

Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.

Nayak B, Dogra PN, Naswa N, Kumar R.

Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):386-93. doi: 10.1007/s00259-012-2294-6. Epub 2012 Nov 24.

PMID:
23179944

Supplemental Content

Support Center